- Home
- ESNT vs RLAY Comparison
ESNT vs RLAY Comparison
Compare ESNT & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- RLAY
- Stock Information
- Founded
- ESNT 2008
- RLAY 2015
- Country
- ESNT Bermuda
- RLAY United States
- Employees
- ESNT N/A
- RLAY N/A
- Industry
- ESNT Property-Casualty Insurers
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESNT Finance
- RLAY Health Care
- Exchange
- ESNT Nasdaq
- RLAY Nasdaq
- Market Cap
- ESNT N/A
- RLAY 576.1M
- IPO Year
- ESNT 2013
- RLAY 2020
- Fundamental
- Price
- ESNT $61.90
- RLAY $3.63
- Analyst Decision
- ESNT Buy
- RLAY Strong Buy
- Analyst Count
- ESNT 7
- RLAY 11
- Target Price
- ESNT $63.29
- RLAY $18.40
- AVG Volume (30 Days)
- ESNT 693.7K
- RLAY 1.6M
- Earning Date
- ESNT 08-01-2025
- RLAY 08-05-2025
- Dividend Yield
- ESNT 2.00%
- RLAY N/A
- EPS Growth
- ESNT 3.49
- RLAY N/A
- EPS
- ESNT 6.84
- RLAY N/A
- Revenue
- ESNT $1,262,105,000.00
- RLAY $7,679,000.00
- Revenue This Year
- ESNT $5.40
- RLAY $14.31
- Revenue Next Year
- ESNT $3.66
- RLAY N/A
- P/E Ratio
- ESNT $9.04
- RLAY N/A
- Revenue Growth
- ESNT 9.57
- RLAY N/A
- 52 Week Low
- ESNT $51.61
- RLAY $1.78
- 52 Week High
- ESNT $65.34
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- ESNT 65.63
- RLAY 63.22
- Support Level
- ESNT $60.34
- RLAY $3.10
- Resistance Level
- ESNT $62.02
- RLAY $3.75
- Average True Range (ATR)
- ESNT 1.06
- RLAY 0.23
- MACD
- ESNT 0.19
- RLAY 0.03
- Stochastic Oscillator
- ESNT 97.53
- RLAY 84.42
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).